Syneos Health to be Acquired by a Private Investment Consortium In $7.1 Billion Deal

Syneos Health to be Acquired by a Private Investment Consortium In $7.1 Billion Deal

Syneos Health is being acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management, Patient Square Capital and Veritas Capital. Completion of the transaction is expected in the second half of 2023. The consortium of private investment firm affiliates is acquiring Syneos for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a 24% premium to Syneos Health’s unaffected closing stock price on February 13, 2023. Upon completion of the transaction, Syneos Health will become a private company and shares of Syneos Health Class A common stock will no longer trade on... Read More »
Discovery Life Sciences Acquires ReachBio Research Labs

Discovery Life Sciences Acquires ReachBio Research Labs

Discovery Life Sciences has acquired ReachBio Research Labs, a Seattle-based contract research organization (CRO). This acquisition will allow Discovery Life Sciences to scale its consolidated drug discovery and preclinical development offerings to give customers access to a broader range of specialized cell biology services. Financial terms of the deal were not disclosed. ReachBio Research Labs specializes in cell-based assays, predictive hematotoxicity and drug screening services. The company provides primary cell biology-based contract research services and products to the drug development and life science research communities. Founded in 2018, Discovery Life Sciences provides... Read More »
Apax Partners Acquires French CRO Porsolt

Apax Partners Acquires French CRO Porsolt

Apax Partners, a London-based private equity firm, announced on February 21 that it acquired a majority stake in Porsolt, a global preclinical contract research organization (CRO) located in Le Genest-Saint-Isle, France. This partnership will enhance Porsolt’s service offering and expand its portfolio and capabilities for drug screening, efficacy and safety for clients worldwide. Terms of the deal were not disclosed. Porsolt works with pharmaceutical and biotechnology companies, academic institutes and not-for-profit organizations, offering specialized preclinical testing services across many disease areas, physiological systems and processes. The funds managed and advised by Apax... Read More »
Apax Partners Acquires French CRO Porsolt

Charles River Laboratories acquires SAMDI Tech for $50 Million

Charles River Laboratories International, Inc. (NYSE: CRL) announced on January 30 that it acquired SAMDI Tech, Inc. The purchase price was $50 million in cash for 80% ownership. Based in Chicago, Illinois, SAMDI Tech offers a proprietary mass spectrometry (MS) technology for high-throughput analysis of biochemical activities and affinity selection MS for identifying binding interactions.  Charles River Laboratories is a provider of research tools and integrated support services that enable drug discovery and development, including genetically and virally defined purpose-bred lab animals. In 2021, the company reported revenue of $3.54 billion. The combination of Charles River’s... Read More »
Apax Partners Acquires French CRO Porsolt

Tigermed Acquires Marti Farm

Hangzhou, China-based Tigermed has acquired Zagreb, Croatia-based Marti Farm. Terms of the deal were not disclosed. Marti Farm is a contract research organization (CRO) dedicated to assisting the healthcare, pharmaceutical and food supplement sectors in developing and delivering health-improving outcomes. The company’s global reach is expanding, with results delivered in more than 50 countries to more than 150 clients. Tigermed is a global provider of integrated research and development solutions for the biopharmaceutical and medical device industries. Tigermed represents a worldwide network of more than 100 subsidiaries and 180 service locations with more than 10,000 employees... Read More »
Apax Partners Acquires French CRO Porsolt

Huma Acquires German CRO Alcedis

Huma Therapeutics Limited, a global digital health company, announced on January 9 its acquisition of Alcedis GmbH for an undisclosed price. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials. Alcedis GmbH is a contract research organization (CRO) for data driven clinical research and technology utilization. Headquartered in Hessen, Germany, Alcedis has more than 25 years of clinical trial experience. Huma Therapeutics produces applications that integrate health data from hospital databases as well as patient wearables and... Read More »